GRIFOLS S.A.

Grifols operates as a plasma therapeutic company globally. It provides various products for treating conditions like immunodeficiencies, liver cirrhosis, and hemophilia. The company also markets diagnostic testing equipment and biological products. Grifols manufactures and sells plasma to third parties and conducts research activities. Its pharmaceutical product portfolio includes Yimmugo PID and ITP, among others. The company has several products in various stages of clinical development, including Phase IV, III, and II.

Overview

Sector

Pharmaceutical

Target Price

5.7 EUR

Current Price

10.8 EUR

Potential

-47%

Strengths

Price to book ratio (1.24) is lower than the sector mean (8.32).
EV/EBITDA (9.97) is lower than the sector mean (21.51).
EV/EBIT (14.59) is lower than the sector mean.
Price to free cash flow (13.75) is lower than the sector mean.
Strong EBITDA Margin of 21.87%.

Weaknesses

With a depreciation Potential of -47.16%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (5.20) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (6.08%) is significantly lower than the sector mean (16.32%).

Indicator	Value
PER	46.5
EV/EBITDA	10.0
Price/Free Cash Flow'	13.8
ROIC	6.1%
Net Debt/EBITDA	5.2

GRIFOLS S.A.

Overview

Strengths

Weaknesses

Key Financial Data